Johnson & Johnson has an operational presence in more than 60 countries and products supplied to over 200 countries worldwide.
Pharmaceutical ETFs are publicly traded securities designed for investors who don’t have the capacity to hold too many stocks but are interested in diversification.
Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.
In 1H17, Gilead Sciences’ (GILD) Viread generated revenues of ~$560 million, compared with $559 in 1H16.
In 1H17, Gilead Sciences’ (GILD) Harvoni reported revenues of ~$2.75 billion, compared with $5.58 billion in 1H16.
In 1H17, Gilead Sciences’ (GILD) TAF (Tenofovir alafenamide) regimen drug Genvoya reported revenues of ~$1.6 billion, compared with $460 million in 1H16.
FDA approval of BIC/FTC/TAF is expected to strengthen Gilead Sciences’ HIV franchise.
In 1H17, Gilead Sciences (GILD) reported revenues of ~$13.4 billion, compared with to $15.6 billion in 1H16.
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
On August 28, 2017, The Medicines Company (MDCO) announced positive data from its Phase 2 trial, ORION-1, evaluating the efficacy of PCSK9 synthesis inhibitor inclisiran.
According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.
In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.
On October 13, 2017, in a Reuters survey comprising 17 brokerages, six (~35.3%) analysts rated Baxter International as a “buy.”
On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.
JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.
JNJ’s Vision Care franchise revenues are expected to increase following the strong performance of new products in all major global markets during 3Q17.
Revenues from JNJ’s Over-the-Counter franchise are expected to increase in 3Q17 due to expected strong sales of QuickMist and Tylenol.